CAGE 9Z482 - BAYLOR COLLEGE OF MEDICINE
USA

BAYLOR COLLEGE OF MEDICINE

CAGE Code: 9Z482
DUNS: 051113330
ONE BAYLOR PLAZA
HOUSTON TX 77030-3411
UNITED STATES

Telephone: 7137981297
Fax: 7137986990

BAYLOR COLLEGE OF MEDICINE is an Active Commercial Supplier with the Cage Code 9Z482 and is tracked by Dun & Bradstreet under DUNS Number 051113330.

Additional Data For CAGE 9Z482

SIC Code 1:8221
Status:A
Type:F
Size:E
Primary Business:N
Type of Business:N
Woman Owned:N
CAO:N66018
ADP CNT CT:N66018

USA Government Contracting Activity for 9Z482

Wednesday, November 29, 2017
$1,041,214.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

F: COOPERATIVE AGREEMENT
THIS PROPOSAL FOR A TRANSLATIONAL RESEARCH INSTITUTE IS SUBMITTED ON BEHALF OF A CONSORTIUM OF NON-PROFIT ACADEMIC INSTITUTIONS IN RESPONSE TO NASA COOPERATIVE AGREEMENT NOTICE NNJ15548000C (CAN), RELEASED OCTOBER 30, 2015. THE CONSORTIUM IS LED BY BAYLOR COLLEGE OF MEDICINE (BCM), AND INCLUDES THE CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH) AND THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT). HRP WAS DESIGNED TO MANAGE AND FUND THE RESEARCH REQUIRED TO UNDERSTAND AND MITIGATE RISKS TO HUMAN HEALTH DURING SPACE FLIGHT MISSIONS. SINCE 2005, HRP HAS WORKED CLOSELY WITH NASA S CHIEF MEDICAL OFFICER, THE HEALTH AND MEDICAL TECHNICAL AUTHORITY, AND THE JOHNSON SPACE CENTER (JSC) HUMAN HEALTH AND PERFORMANCE DIRECTORATE TO DEFINE AND PRIORITIZE RISKS TO HUMANS DURING VARIOUS TYPES OF SPACE EXPLORATION MISSION. ONCE THE HIGHEST RISKS WERE IDENTIFIED, THE HRP DETERMINED RESEARCH PLANS (DOCUMENTED IN THE HRR) TO ADDRESS GAPS IN KNOWLEDGE AND DESCRIBE MITIGATION STRATEGIES FOR CONTROLLING EACH RISK. THESE RESEARCH PLANS HAVE SINCE BEEN THE BASIS FOR SOLICITED AND DIRECTED RESEARCH PROJECTS THAT ADD TO THE KNOWLEDGE BASE OF EACH RISK AND MAKE PROGRESS TOWARD FEASIBLE COUNTERMEASURES. THIS STRATEGY HAS PROVEN TO BE QUITE EFFECTIVE; COUNTERMEASURES HAVE BEEN DEVELOPED TO ADEQUATELY PREVENT, CONTROL OR TREAT MANY RISKS IN MULTIPLE MISSION SCENARIOS.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AO69A  
Wednesday, November 22, 2017
$5,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
DOSE TRACKER APPLICATION FOR MONITORING CREW MEDICATION USAGE, SYMPTOMS, AND ADVERSE EFFECTS DURING MISSIONS DO MEDICATIONS USED DURING SPACEFLIGHTS WORK THE SAME AS THEY DO ON EARTH? THIS SINGLE QUESTION UNDERLIES MOST OF THE UNKNOWNS WITHIN NASA S HUMAN RESEARCH PROGRAM RISK OF CLINICALLY RELEVANT UNPREDICTED EFFECTS OF MEDICATION. DURING SPACEFLIGHT, THE BODY UNDERGOES A NUMBER OF PHYSIOLOGICAL CHANGES THAT ARE EXPECTED TO RESULT IN ALTERED INTERACTIONS WITH ADMINISTERED MEDICATIONS, BUT IT IS NOT YET KNOWN IF, OR TO WHAT EXTENT, THESE ACTUALLY OCCUR. THE POTENTIAL FOR THERAPEUTICALLY RELEVANT ALTERATION IN EITHER PHARMACOKINETICS (HOW THE BODY HANDLES ADMINISTERED MEDICATIONS) OR PHARMACODYNAMICS (HOW ADMINISTERED MEDICATIONS ACT UPON THE BODY) HAS LONG BEEN A CONCERN. THIS OBSERVATIONAL EPIDEMIOLOGICAL STUDY IS A PROACTIVE STEP TOWARD ADDRESSING THIS ISSUE VIA REGULAR DIRECT QUESTIONING OF CREWMEMBER VOLUNTEERS, A MODEL THAT THE JSC NUTRITIONAL BIOCHEMISTRY DISCIPLINE HAS PROVEN TO BE BOTH FEASIBLE AND USEFUL. A TABLET- OR HANDHELD DEVICE-BASED QUESTIONNAIRE WILL BE USED TO PERMIT FAST AND EFFICIENT COLLECTION OF DATA REGARDING CREWMEMBERS MEDICATION USE ON A NEAR REAL-TIME BASIS, ELIMINATING THE CURRENT PROBLEMS ASSOCIATED WITH RECALL OVER PERIODS OF WEEKS. SPECIFIC QUESTIONS REGARDING MEDICATION USE (SOMEWHAT DIFFERENT FROM THE QUESTIONS THAT PHYSICIANS ASK REGARDING PATIENT HEALTH) WILL BE ASKED OF EACH PARTICIPATING CREWMEMBER. THE DATA COLLECTION PROCESS WILL BE STREAMLINED BY USING A FLEXIBLY PROGRAMMED COMPUTERIZED SURVEY APPLICATION THAT LEVERAGES THE LIMITED MEDICATION CHOICES ABOARD, THE DOSES AVAILABLE, TYPICAL DOSING FREQUENCY, AND SIDE EFFECTS ASSOCIATED WITH EACH MEDICATION TO PROVIDE AN INDIVIDUALIZED SHORT QUESTIONNAIRE FOR EACH MEDICATION USE BY THE CREWMEMBER. CODED (DE-IDENTIFIED) DATA WILL BE DELIVERED WEEKLY TO A SECURE SERVER ON THE GROUND FOR ANALYSIS BY STUDY INVESTIGATORS. POST-FLIGHT (AFTER RE-ADAPTATION TO EARTH S GRAVITY), EACH PARTICIPATING CREWMEMBER WILL REPEAT RECORDING THEIR MEDICATION USAGE, SO THAT THEIR GROUND MEDICATION USAGE FREQUENCIES, DOSES, AND PERCEPTIONS MAY BE COMPARED TO THOSE RECORDED DURING FLIGHT.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AK78G  
Friday, October 27, 2017
$50,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
THIS PROPOSAL OUTLINES THE PLAN FOR MONITORING THE PHYSIOLOGICAL AND ANATOMICAL EFFECTS OF TWO DIFFERENT REGIMENS OF INTERMITTENT CENTRIFUGATION INDUCED ARTIFICIAL GRAVITY WITH FOCUS ON THE BRAIN, EYE, AND VESTIBULAR SYSTEM RESPONSES. THE SPECIFIC AIMS WILL INCLUDE: 1. INTEGRATIVE EVALUATION OF THE CEREBRAL PHYSIOLOGICAL EFFECTS OF AG DURING THE 60 DAY BED REST PERIOD USING BETWEEN GROUP AND WITHIN GROUP COMPARISONS, AND 2. ASSESSMENT OF THE ACUTE DYNAMIC CHANGES IN THE HUMAN BODY SYSTEMS RELATED TO THE CENTRIFUGATION REGIMEN. THE METHODS AND TECHNIQUES USED TO ACHIEVE THESE OBJECTIVES INCLUDE: NON-INVASIVE ASSESSMENT OF ICP, CEREBRAL BLOOD FLOW, CEREBRAL BLOOD VOLUME, CSF FLOW AND VOLUMES, OCULAR ANATOMY AND PHYSIOLOGY, AND NEUROVESTIBULAR FUNCTION. THIS PROPOSAL WILL DELIVER AN INTEGRATED VIEW OF THE PHYSIOLOGICAL, ANATOMICAL AND FUNCTIONAL EFFECTS OF INTERMITTENT CENTRIFUGATION (ARTIFICIAL GRAVITY) ON THE CEREBROVASCULAR, OCULAR AND VESTIBULAR SYSTEMS. THIS WILL PROVIDE IMPORTANT INSIGHTS INTO THE EFFECTIVENESS OF THIS FORM OF ARTIFICIAL GRAVITY TO COUNTERACT THE HEADWARD FLUID SHIFTING OF HEAD DOWN TILT; WHICH MAY YIELD IMPORTANT KNOWLEDGE ABOUT THE FUTURE UTILITY OF THIS METHOD AS A COUNTERMEASURE FOR THE SPACE-FLIGHT INDUCED HEADWARD FLUID SHIFTS AND THE VIIP SYNDROME.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX17AE04G  
Thursday, October 19, 2017
$1,940.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
TO ATTEND BASE IDIQ KICK-OFF MEETING.
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN27200002     HHSN272201700013I     NIHAI2016059  
Thursday, October 19, 2017
($46,731.00)
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

D: DEFINITIVE CONTRACT
IGF::CT::IGF, MICROBIOLOGIST SERVICES BASE YEAR - 07-01-2016 THROUGH 06-30-2017. DECREASE CONTRACT CLOSEOUT.
Q301: MEDICAL- LABORATORY TESTING

  VA25616C0113     VA256-16-R-0111  
Wednesday, October 18, 2017
$1,875.00
3600: Department of Veterans Affairs
36C506: 506-ANN ARBOR (00506)

D: DEFINITIVE CONTRACT
IGF::OT::IGF PRINCIPAL RESEARCH INVESTIGATOR ON HSR&D PROJECT.
R497: SUPPORT- PROFESSIONAL: PERSONAL SERVICES CONTRACTS

  VA25115C0187     VA251-15-Q-0422  
Sunday, October 1, 2017
$245,738.98
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

C: DELIVERY ORDER
IGF::CT::IGF LIVER KIDNEY TRANSPLANT SERVICES, TASK ORDER FROM IDIQ CONTRACT, PERIOD OF PERFORMANCE 10-01-2017 THROUGH 03-31-2018.
Q523: MEDICAL- SURGERY

  36C25618N0012     VA25617D0218  
Sunday, October 1, 2017
$0.00
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

B: IDC
IGF::CT::IGF LIVER KIDNEY TRANSPLANT SERVICES, PERIOD OF PERFORMANCE 10-01-2017 THROUGH 03-31-2018.
Q523: MEDICAL- SURGERY

  VA25617D0218     VA256-17-Q-1525  
Sunday, October 1, 2017
$63,096.00
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

D: DEFINITIVE CONTRACT
ANIMAL CARE FACILITY IGF::CL::IGF
R416: SUPPORT- PROFESSIONAL: VETERINARY/ANIMAL CARE

  VA25614C0214     VA256-15-R-1471  
Wednesday, September 27, 2017
$25,709.59
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
THIS PROPOSAL AIMS TO EVALUATE THE IMPACT OF SPACE BIOMEDICAL RESEARCH ON OPERATIONAL SPACE MEDICINE AS IT RELATES TO NASA HEADQUARTERS POLICY AND OVERSIGHT RESPONSIBILITIES. TO ACHIEVE THIS GOAL, THE CENTER FOR SPACE MEDICINE AT BAYLOR COLLEGE OF MEDICINE WILL ASSIGN AN OUTSTANDING PHYSICIAN-SCIENTIST WITH DOMAIN EXPERTISE TO THE NASA HEADQUARTERS OFFICES OF THE HUMAN EXPLORATION AND OPERATIONS MISSION DIRECTORATE AND THE CHIEF HEALTH AND MEDICAL OFFICER. AN ONGOING REVIEW AND EVALUATION OF DESIGNED METRICS WILL BE PERFORMED FOCUSING ON RESEARCH MERIT AND RELEVANCE, USE OF HUMAN SUBJECTS, THE TRANSITION OF RESEARCH DELIVERABLES TO MEDICAL PRACTICE, AND OUTCOMES INFORMING MEDICAL STANDARDS, REQUIREMENTS AND IMPROVEMENTS. THE RESULTS WILL BE USED TO REFINE RESEARCH ACTIVITIES AND OPERATIONAL MEDICINE NEEDS FOR EXPLORATION MISSIONS.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  80NSSC17K0708  
Monday, September 25, 2017
$0.00
7500: Department of Health and Human Services
75N920: NATIONAL INSTITUTES OF HEALTH NHLBI

C: DELIVERY ORDER
IGF::OT::IGF CENTRALIZED OMICS RESOURCE (CORE)
B599: SPECIAL STUDIES/ANALYSIS- OTHER

  HHSN26800002     HHSN268201600033I     NHLBICSBHV201636JES  
Monday, September 25, 2017
$622,090.41
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE TREATMENT AND EVALUATION UNITS (VTEU); THE PURPOSE OF THIS TASK ORDER IS TO TRANSFER ACTIVE WORK FROM HHSN272200800002C TO THE IDIQ VTEU CONTRACT, HHSN27220130015I.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200016     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Friday, September 22, 2017
$4,500.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
CORNEA 17-7399
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P7179  
Friday, September 22, 2017
$4,650.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
CORNEA
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P7178  
Friday, September 22, 2017
$4,800.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
CORNEA 17-7205
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P7180  
Friday, September 22, 2017
$199,152.00
7500: Department of Health and Human Services
75D301: CDC OFFICE OF ACQUISITION SERVICES

D: DEFINITIVE CONTRACT
IGF::OT::IGF BAYLOR COLLEGE OF MEDICINE RESEARCH
AJ51: R&D- GENERAL SCIENCE/TECHNOLOGY: LIFE SCIENCES (BASIC RESEARCH)

  HHSD200201795100C     2017N67337  
Monday, September 18, 2017
$4,695,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

F: COOPERATIVE AGREEMENT
THIS PROPOSAL FOR A TRANSLATIONAL RESEARCH INSTITUTE IS SUBMITTED ON BEHALF OF A CONSORTIUM OF NON-PROFIT ACADEMIC INSTITUTIONS IN RESPONSE TO NASA COOPERATIVE AGREEMENT NOTICE NNJ15548000C (CAN), RELEASED OCTOBER 30, 2015. THE CONSORTIUM IS LED BY BAYLOR COLLEGE OF MEDICINE (BCM), AND INCLUDES THE CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH) AND THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT). HRP WAS DESIGNED TO MANAGE AND FUND THE RESEARCH REQUIRED TO UNDERSTAND AND MITIGATE RISKS TO HUMAN HEALTH DURING SPACE FLIGHT MISSIONS. SINCE 2005, HRP HAS WORKED CLOSELY WITH NASA S CHIEF MEDICAL OFFICER, THE HEALTH AND MEDICAL TECHNICAL AUTHORITY, AND THE JOHNSON SPACE CENTER (JSC) HUMAN HEALTH AND PERFORMANCE DIRECTORATE TO DEFINE AND PRIORITIZE RISKS TO HUMANS DURING VARIOUS TYPES OF SPACE EXPLORATION MISSION. ONCE THE HIGHEST RISKS WERE IDENTIFIED, THE HRP DETERMINED RESEARCH PLANS (DOCUMENTED IN THE HRR) TO ADDRESS GAPS IN KNOWLEDGE AND DESCRIBE MITIGATION STRATEGIES FOR CONTROLLING EACH RISK. THESE RESEARCH PLANS HAVE SINCE BEEN THE BASIS FOR SOLICITED AND DIRECTED RESEARCH PROJECTS THAT ADD TO THE KNOWLEDGE BASE OF EACH RISK AND MAKE PROGRESS TOWARD FEASIBLE COUNTERMEASURES. THIS STRATEGY HAS PROVEN TO BE QUITE EFFECTIVE; COUNTERMEASURES HAVE BEEN DEVELOPED TO ADEQUATELY PREVENT, CONTROL OR TREAT MANY RISKS IN MULTIPLE MISSION SCENARIOS.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AO69A  
Friday, September 15, 2017
$293,890.90
7500: Department of Health and Human Services
75D301: CDC OFFICE OF ACQUISITION SERVICES

D: DEFINITIVE CONTRACT
IGF::OT::IGF
AZ11: R&D- OTHER RESEARCH AND DEVELOPMENT (BASIC RESEARCH)

  HHSD200201796080C     2017N67607  
Wednesday, September 13, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
CORNEA
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P6875  
Tuesday, September 12, 2017
$4,650.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
CORNEA, WHOLE
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P6823  
Tuesday, September 12, 2017
$0.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
CREWMEMBERS ON SPACEFLIGHT MISSIONS USE MEDICATIONS TO TREAT SPACEFLIGHT-ASSOCIATED CONDITIONS LIKE SPACE ADAPTATION SYNDROME AS WELL AS COMMON ORDINARY COMPLAINTS. THEY DO SO UNDER THE REMOTE GUIDANCE OF THEIR FLIGHT SURGEONS, WHO BASE PRESCRIPTIONS ON THEIR KNOWLEDGE AND EXPERIENCE IN TERRESTRIAL MEDICINE. HOWEVER, EVEN AFTER DECADES OF SPACEFLIGHT MISSIONS, WE DO NOT KNOW IF MEDICATIONS ACT THE SAME IN THE SPACEFLIGHT ENVIRONMENT AS THEY DO ON EARTH. ASPECTS OF THE SPACEFLIGHT ENVIRONMENT (LOW GRAVITY, RADIATION EXPOSURE, CLOSED ENVIRONMENT, STRESS) HAVE BEEN SHOWN TO ALTER HUMAN PHYSIOLOGY. FROM FIRST PRINCIPLES, SOME OF THESE PHYSIOLOGICAL CHANGES COULD BE EXPECTED TO ALTER EITHER PHARMACOKINETICS (PK, HOW THE BODY ABSORBS, DISTRIBUTES, METABOLIZE AND EXCRETES ADMINISTERED MEDICATIONS) OR PHARMACODYNAMICS (PD, RECEPTORS OR SIGNALLING SYSTEMS THAT ARE THE TARGETS OF MEDICATION ACTION). ANECDOTAL DATA HAS SUGGESTED THAT, AT LEAST FOR CERTAIN MEDICATIONS OR INDICATIONS, INFLIGHT MEDICATION EFFICACY IS POOR, AND SPACEFLIGHT CREW USE HIGH DOSES, REPEATED DOSES, OR EVEN EXPERIENCE APPARENT TREATMENT FAILURES; FORTUNATELY NONE OF THESE EPISODES HAS BEEN SERIOUS ENOUGH TO CAUSE INJURY OR EVACUATION FROM LOW-EARTH ORBIT (LEO). HOWEVER, IN ORDER TO PREPARE FOR EXPLORATION MISSIONS WHERE SPEEDY EVACUATION TO EARTH MAY NOT BE A POSSIBILITY, THE LIKELIHOOD OF UNEXPECTED MEDICATION ACTION MUST BE DETERMINED. NEW STUDIES HAVE YIELDED THE FIRST DOCUMENTED EVIDENCE OF APPARENT TREATMENT FAILURES IN LOW EARTH ORBIT. THESE INSTANCES COULD BE EXPLAINED BY ALTERATIONS IN PK OR PD. THE CENTRAL HYPOTHESIS OF THIS PROPOSAL IS THAT THE SPACEFLIGHT ENVIRONMENT ALTERS HUMAN PHYSIOLOGY IN WAYS THAT AFFECT HOW MEDICATIONS ULTIMATELY EXERT THEIR ACTIONS, EITHER BY CHANGING PK OR PD. SPECIFICALLY, WE PROPOSE TO: (1) TEST THE HYPOTHESIS THAT PK FOLLOWING ADMINISTRATION OF A MEDICATION IS DIFFERENT DURING SPACEFLIGHT AS COMPARED TO GROUNDBASED DATA FROM THE SAME SUBJECT, AND (2) TEST THE HYPOTHESIS THAT MEDICATION ACTION (PD) IS DIFFERENT DURING SPACEFLIGHT AS COMPARED TO GROUND-BASED DATA FROM THE SAME SUBJECT. WE PROPOSE TO TEST OUR HYPOTHESIS WITH THREE UNRELATED MEDICATIONS COMMONLY USED ON SPACEFLIGHT MISSIONS: A NONBENZODIAZEPINE HYPNOTIC, A STIMULANT, AND AN ANTIHISTAMINE WITH ANTINAUSEA ACTION. THESE MEDICATIONS ALL HAVE TARGETS IN THE CENTRAL NERVOUS SYSTEM, AND SHARE ACTION ON SLEEP OR WAKEFULNESS, PERMITTING USE OF THE SAME SUITE OF PD MEASURES. WE PROPOSE TO MEASURE PK FOR 3 MEDICATIONS FREQUENTLY USED BY CREWMEMBERS IN TWO DIFFERENT ENVIRONMENTS: ON EARTH AND DURING A SPACEFLIGHT MISSION. CIRCULATING CONCENTRATIONS IN THE BLOODSTREAM WILL BE MEASURED OVER TIME AFTER MEDICATION ADMINISTRATION, PERMITTING MODELED ESTIMATION OF ABSORPTION RATES AND METABOLISM/EXCRETION RATES. SAME-SUBJECT COMPARISONS USING PRE-FLIGHT AND POST-FLIGHT TEST SESSIONS WILL PERMIT MEASUREMENT OF SAME-SUBJECT VARIABILITY THAT WILL PROVIDE A BASELINE FOR DETERMINATION OF CLINICALLY RELEVANT CHANGES DURING SPACEFLIGHT. SPACEFLIGHT VS. GROUND DIFFERENCES IN MEDICATION-ASSOCIATED EFFECTS ON SLEEP, WAKEFULNESS, AND SEVERAL MEASURES OF COGNITIVE FUNCTION WILL BE USED AS MEASURES OF PHARMCODYNAMICS.THIS STUDY WILL DETERMINE IF THE LEO ENVIRONMENT OF THE ISS ALTERS THE ACTIONS OF THREE COMMON MEDICATIONS. A LIKELY OUTCOME, RELEVANT FOR NASA MISSIONS, IS OPTIMIZED DOSING RECOMMENDATIONS FOR ONE OR MORE OF THESE MEDICATIONS. IN MORE GENERAL TERMS, THE RESULTS OF THIS STUDY WILL INDICATE THE LIKELIHOOD AND MAGNITUDE OF ANY SPACEFLIGHT-ASSOCIATED PK OR PD CHANGES, AND THUS HELP TO DETERMINE FUTURE RESEARCH PRIORITIES. THE GENERAL POPULATION, WHO ALSO USE THESE MEDICATIONS, ARE ALSO LIKELY TO BENEFIT FROM ADDITIONAL UNDERSTANDING OF HOW THESE MEDICATIONS INTERACT WITH THE HUMAN BODY.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AG97G  
Tuesday, September 12, 2017
$4,500.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
WHOLE CORNEA
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P6851  
Tuesday, September 12, 2017
$4,800.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
CORNEA, WHOLE
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P6855  
Tuesday, September 12, 2017
$4,050.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
WHOLE CORNEA
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P6853  
Monday, August 28, 2017
($108,987.58)
7500: Department of Health and Human Services
75D301: CDC OFFICE OF ACQUISITION SERVICES

D: DEFINITIVE CONTRACT
IMPLEMENTATION AND EVALUATION COMPREHENSIVE POSITIVES HIV INTERVENTION/MODIFICATION TO EXTEND POP
AQ91: R&D- SOCIAL SERVICES: OTHER (BASIC RESEARCH)

  HHSD200201141982C     2011N13271  
Thursday, August 24, 2017
$3,720.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
IMPLANT
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P6196  
Thursday, August 24, 2017
$0.00
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

D: DEFINITIVE CONTRACT
ANIMAL CARE FACILITY IGF::CL::IGF
R416: SUPPORT- PROFESSIONAL: VETERINARY/ANIMAL CARE

  VA25614C0214     VA256-15-R-1471  
Tuesday, August 22, 2017
$275,333.00
7500: Department of Health and Human Services
75N920: NATIONAL INSTITUTES OF HEALTH NHLBI

C: DELIVERY ORDER
IGF::OT::IGF - PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES CELL MANUFACTURING AND PROCESS DEVELOPMENT SERVICES FOR RSA PCT0005-01: DEVELOPMENT OF AN EFFICIENT T CELL TRANSDUCTION STRATEGY
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN26800002     HHSN268201600015I     NHLBIECBHB201609JB  
Tuesday, August 22, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
CORNEA, WHOLE
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P6475  
Thursday, August 17, 2017
$507,477.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; VTEU PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS: A PROSPECTIVE NATURAL HISTORY STUDY OF US PATIENTS WITH A HISTORY OF ZIKA VIRUS INFECTION
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200008     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Tuesday, August 15, 2017
$359,166.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; VACCINE TREATMENT EVALUATION UNITS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200005     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Tuesday, August 15, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
CORNEAL TRANSPLANT STATUS
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P6086  
Friday, August 11, 2017
$6,750.00
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

B: PURCHASE ORDER
IGF::OT::IGF BAYLOR COLLEGE OF MEDICINE INC 1088193 [17-010625]
Q301: MEDICAL- LABORATORY TESTING

  HHSN275201700626P  
Friday, August 11, 2017
$13,469.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE TREATMENT AND EVALUATION UNITS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200010     HHSN272201300015I     FY.2017.A1B1C1D1.0048  
Tuesday, August 8, 2017
$43,457.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; VACCINE TREATMENT EVALUATION UNITS (EXTENSION)
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200006     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Thursday, August 3, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
CORNEA, WHOLE
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P5742  
Monday, July 31, 2017
$40,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
DOSE TRACKER APPLICATION FOR MONITORING CREW MEDICATION USAGE, SYMPTOMS, AND ADVERSE EFFECTS DURING MISSIONS DO MEDICATIONS USED DURING SPACEFLIGHTS WORK THE SAME AS THEY DO ON EARTH? THIS SINGLE QUESTION UNDERLIES MOST OF THE UNKNOWNS WITHIN NASA S HUMAN RESEARCH PROGRAM RISK OF CLINICALLY RELEVANT UNPREDICTED EFFECTS OF MEDICATION. DURING SPACEFLIGHT, THE BODY UNDERGOES A NUMBER OF PHYSIOLOGICAL CHANGES THAT ARE EXPECTED TO RESULT IN ALTERED INTERACTIONS WITH ADMINISTERED MEDICATIONS, BUT IT IS NOT YET KNOWN IF, OR TO WHAT EXTENT, THESE ACTUALLY OCCUR. THE POTENTIAL FOR THERAPEUTICALLY RELEVANT ALTERATION IN EITHER PHARMACOKINETICS (HOW THE BODY HANDLES ADMINISTERED MEDICATIONS) OR PHARMACODYNAMICS (HOW ADMINISTERED MEDICATIONS ACT UPON THE BODY) HAS LONG BEEN A CONCERN. THIS OBSERVATIONAL EPIDEMIOLOGICAL STUDY IS A PROACTIVE STEP TOWARD ADDRESSING THIS ISSUE VIA REGULAR DIRECT QUESTIONING OF CREWMEMBER VOLUNTEERS, A MODEL THAT THE JSC NUTRITIONAL BIOCHEMISTRY DISCIPLINE HAS PROVEN TO BE BOTH FEASIBLE AND USEFUL. A TABLET- OR HANDHELD DEVICE-BASED QUESTIONNAIRE WILL BE USED TO PERMIT FAST AND EFFICIENT COLLECTION OF DATA REGARDING CREWMEMBERS MEDICATION USE ON A NEAR REAL-TIME BASIS, ELIMINATING THE CURRENT PROBLEMS ASSOCIATED WITH RECALL OVER PERIODS OF WEEKS. SPECIFIC QUESTIONS REGARDING MEDICATION USE (SOMEWHAT DIFFERENT FROM THE QUESTIONS THAT PHYSICIANS ASK REGARDING PATIENT HEALTH) WILL BE ASKED OF EACH PARTICIPATING CREWMEMBER. THE DATA COLLECTION PROCESS WILL BE STREAMLINED BY USING A FLEXIBLY PROGRAMMED COMPUTERIZED SURVEY APPLICATION THAT LEVERAGES THE LIMITED MEDICATION CHOICES ABOARD, THE DOSES AVAILABLE, TYPICAL DOSING FREQUENCY, AND SIDE EFFECTS ASSOCIATED WITH EACH MEDICATION TO PROVIDE AN INDIVIDUALIZED SHORT QUESTIONNAIRE FOR EACH MEDICATION USE BY THE CREWMEMBER. CODED (DE-IDENTIFIED) DATA WILL BE DELIVERED WEEKLY TO A SECURE SERVER ON THE GROUND FOR ANALYSIS BY STUDY INVESTIGATORS. POST-FLIGHT (AFTER RE-ADAPTATION TO EARTH S GRAVITY), EACH PARTICIPATING CREWMEMBER WILL REPEAT RECORDING THEIR MEDICATION USAGE, SO THAT THEIR GROUND MEDICATION USAGE FREQUENCIES, DOSES, AND PERCEPTIONS MAY BE COMPARED TO THOSE RECORDED DURING FLIGHT.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AK78G  
Thursday, July 27, 2017
$3,900,915.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; 1300015I BAYLOR COLLEGE OF MEDICINE; VTEU; TO FY.2017.B8C12.0080--15 TASK AREA B-C PHASE II VACCINE TRIAL FOR INFLUENZA; H7N9 FLU CAN 8030247; $3,900,915
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200015     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Friday, July 14, 2017
($4,711,282.20)
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

D: DEFINITIVE CONTRACT
THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE FUNDS ON VARIOUS OPTIONS WHERE WORK HAS BEEN COMPLETED.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272200800002C  
Thursday, July 13, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

B: IDC
IGF::OT::IGF PRE-CLINICAL MODELS OF INFECTIOUS DISEASES
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN272201700013I     NIHAI2016059  
Wednesday, July 12, 2017
$273,387.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; VACCINE AND TREATMENT EVALUATION UNITS (VTEU)
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200014     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Friday, July 7, 2017
$66,345.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
CREWMEMBERS ON SPACEFLIGHT MISSIONS USE MEDICATIONS TO TREAT SPACEFLIGHT-ASSOCIATED CONDITIONS LIKE SPACE ADAPTATION SYNDROME AS WELL AS COMMON ORDINARY COMPLAINTS. THEY DO SO UNDER THE REMOTE GUIDANCE OF THEIR FLIGHT SURGEONS, WHO BASE PRESCRIPTIONS ON THEIR KNOWLEDGE AND EXPERIENCE IN TERRESTRIAL MEDICINE. HOWEVER, EVEN AFTER DECADES OF SPACEFLIGHT MISSIONS, WE DO NOT KNOW IF MEDICATIONS ACT THE SAME IN THE SPACEFLIGHT ENVIRONMENT AS THEY DO ON EARTH. ASPECTS OF THE SPACEFLIGHT ENVIRONMENT (LOW GRAVITY, RADIATION EXPOSURE, CLOSED ENVIRONMENT, STRESS) HAVE BEEN SHOWN TO ALTER HUMAN PHYSIOLOGY. FROM FIRST PRINCIPLES, SOME OF THESE PHYSIOLOGICAL CHANGES COULD BE EXPECTED TO ALTER EITHER PHARMACOKINETICS (PK, HOW THE BODY ABSORBS, DISTRIBUTES, METABOLIZE AND EXCRETES ADMINISTERED MEDICATIONS) OR PHARMACODYNAMICS (PD, RECEPTORS OR SIGNALLING SYSTEMS THAT ARE THE TARGETS OF MEDICATION ACTION). ANECDOTAL DATA HAS SUGGESTED THAT, AT LEAST FOR CERTAIN MEDICATIONS OR INDICATIONS, INFLIGHT MEDICATION EFFICACY IS POOR, AND SPACEFLIGHT CREW USE HIGH DOSES, REPEATED DOSES, OR EVEN EXPERIENCE APPARENT TREATMENT FAILURES; FORTUNATELY NONE OF THESE EPISODES HAS BEEN SERIOUS ENOUGH TO CAUSE INJURY OR EVACUATION FROM LOW-EARTH ORBIT (LEO). HOWEVER, IN ORDER TO PREPARE FOR EXPLORATION MISSIONS WHERE SPEEDY EVACUATION TO EARTH MAY NOT BE A POSSIBILITY, THE LIKELIHOOD OF UNEXPECTED MEDICATION ACTION MUST BE DETERMINED. NEW STUDIES HAVE YIELDED THE FIRST DOCUMENTED EVIDENCE OF APPARENT TREATMENT FAILURES IN LOW EARTH ORBIT. THESE INSTANCES COULD BE EXPLAINED BY ALTERATIONS IN PK OR PD. THE CENTRAL HYPOTHESIS OF THIS PROPOSAL IS THAT THE SPACEFLIGHT ENVIRONMENT ALTERS HUMAN PHYSIOLOGY IN WAYS THAT AFFECT HOW MEDICATIONS ULTIMATELY EXERT THEIR ACTIONS, EITHER BY CHANGING PK OR PD. SPECIFICALLY, WE PROPOSE TO: (1) TEST THE HYPOTHESIS THAT PK FOLLOWING ADMINISTRATION OF A MEDICATION IS DIFFERENT DURING SPACEFLIGHT AS COMPARED TO GROUNDBASED DATA FROM THE SAME SUBJECT, AND (2) TEST THE HYPOTHESIS THAT MEDICATION ACTION (PD) IS DIFFERENT DURING SPACEFLIGHT AS COMPARED TO GROUND-BASED DATA FROM THE SAME SUBJECT. WE PROPOSE TO TEST OUR HYPOTHESIS WITH THREE UNRELATED MEDICATIONS COMMONLY USED ON SPACEFLIGHT MISSIONS: A NONBENZODIAZEPINE HYPNOTIC, A STIMULANT, AND AN ANTIHISTAMINE WITH ANTINAUSEA ACTION. THESE MEDICATIONS ALL HAVE TARGETS IN THE CENTRAL NERVOUS SYSTEM, AND SHARE ACTION ON SLEEP OR WAKEFULNESS, PERMITTING USE OF THE SAME SUITE OF PD MEASURES. WE PROPOSE TO MEASURE PK FOR 3 MEDICATIONS FREQUENTLY USED BY CREWMEMBERS IN TWO DIFFERENT ENVIRONMENTS: ON EARTH AND DURING A SPACEFLIGHT MISSION. CIRCULATING CONCENTRATIONS IN THE BLOODSTREAM WILL BE MEASURED OVER TIME AFTER MEDICATION ADMINISTRATION, PERMITTING MODELED ESTIMATION OF ABSORPTION RATES AND METABOLISM/EXCRETION RATES. SAME-SUBJECT COMPARISONS USING PRE-FLIGHT AND POST-FLIGHT TEST SESSIONS WILL PERMIT MEASUREMENT OF SAME-SUBJECT VARIABILITY THAT WILL PROVIDE A BASELINE FOR DETERMINATION OF CLINICALLY RELEVANT CHANGES DURING SPACEFLIGHT. SPACEFLIGHT VS. GROUND DIFFERENCES IN MEDICATION-ASSOCIATED EFFECTS ON SLEEP, WAKEFULNESS, AND SEVERAL MEASURES OF COGNITIVE FUNCTION WILL BE USED AS MEASURES OF PHARMCODYNAMICS.THIS STUDY WILL DETERMINE IF THE LEO ENVIRONMENT OF THE ISS ALTERS THE ACTIONS OF THREE COMMON MEDICATIONS. A LIKELY OUTCOME, RELEVANT FOR NASA MISSIONS, IS OPTIMIZED DOSING RECOMMENDATIONS FOR ONE OR MORE OF THESE MEDICATIONS. IN MORE GENERAL TERMS, THE RESULTS OF THIS STUDY WILL INDICATE THE LIKELIHOOD AND MAGNITUDE OF ANY SPACEFLIGHT-ASSOCIATED PK OR PD CHANGES, AND THUS HELP TO DETERMINE FUTURE RESEARCH PRIORITIES. THE GENERAL POPULATION, WHO ALSO USE THESE MEDICATIONS, ARE ALSO LIKELY TO BENEFIT FROM ADDITIONAL UNDERSTANDING OF HOW THESE MEDICATIONS INTERACT WITH THE HUMAN BODY.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AG97G  
Wednesday, July 5, 2017
$1,960,847.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; VACCINE TREATMENT EVALUATION UNITS (EXTENSION)
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200006     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Friday, June 30, 2017
$115,447.00
7500: Department of Health and Human Services
75N920: NATIONAL INSTITUTES OF HEALTH NHLBI

C: DELIVERY ORDER
IGF::OT::IGF - PRODUCTION ASSISTANCE FOR CELLULAR THERAPIES (PACT)- CELL PROCESSING FACILITIES
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN26800001     HHSN268201600015I     NHLBIECBHB201609JB  
Wednesday, June 28, 2017
$49,000.00
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

B: PURCHASE ORDER
DIGESTIVES CORE SERVICES IGF::OT::IGF
R499: SUPPORT- PROFESSIONAL: OTHER

  VA25617P1295     VA256-17-Q-0938  
Monday, June 19, 2017
$121,471.97
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

C: DELIVERY ORDER
IGF::CT::IGF LIVER KIDNEY TRANSPLANT SERVICES TASK ORDER ISSUED FROM IDIQ CONTRACT. PERIOD OF PERFORMANCE 07-01-2017 THROUGH 09-30-2017.
Q523: MEDICAL- SURGERY

  VA25617J0295     VA25616D0126  
Monday, June 19, 2017
$0.00
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

B: IDC
IGF::CT::IGF LIVER KIDNEY TRANSPLANT SERVICES, PERIOD OF PERFORMANCE 07-01-2017 THROUGH 09-30-2017.
Q523: MEDICAL- SURGERY

  VA25616D0126     VA256-16-R-0832  
Tuesday, June 13, 2017
$96,260.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; 1300015I THIS MODIFICATION IS ISSUED TO EXTEND THE PERIOD OF PERFORMANCE, ADD FUNDING AND UPDATE VARIOUS ARTICLES AND CLAUSES.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200004     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Tuesday, June 13, 2017
$259,824.83
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

D: DEFINITIVE CONTRACT
THE PURPOSE OF THIS MODIFICATION IS TO REOBLIGATE FUNDS ON VARIOUS OPTIONS TO PAY OUTSTANDING INVOICES.
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272200800002C  
Friday, June 9, 2017
$600,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

F: COOPERATIVE AGREEMENT
THIS PROPOSAL FOR A TRANSLATIONAL RESEARCH INSTITUTE IS SUBMITTED ON BEHALF OF A CONSORTIUM OF NON-PROFIT ACADEMIC INSTITUTIONS IN RESPONSE TO NASA COOPERATIVE AGREEMENT NOTICE NNJ15548000C (CAN), RELEASED OCTOBER 30, 2015. THE CONSORTIUM IS LED BY BAYLOR COLLEGE OF MEDICINE (BCM), AND INCLUDES THE CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH) AND THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT). HRP WAS DESIGNED TO MANAGE AND FUND THE RESEARCH REQUIRED TO UNDERSTAND AND MITIGATE RISKS TO HUMAN HEALTH DURING SPACE FLIGHT MISSIONS. SINCE 2005, HRP HAS WORKED CLOSELY WITH NASA S CHIEF MEDICAL OFFICER, THE HEALTH AND MEDICAL TECHNICAL AUTHORITY, AND THE JOHNSON SPACE CENTER (JSC) HUMAN HEALTH AND PERFORMANCE DIRECTORATE TO DEFINE AND PRIORITIZE RISKS TO HUMANS DURING VARIOUS TYPES OF SPACE EXPLORATION MISSION. ONCE THE HIGHEST RISKS WERE IDENTIFIED, THE HRP DETERMINED RESEARCH PLANS (DOCUMENTED IN THE HRR) TO ADDRESS GAPS IN KNOWLEDGE AND DESCRIBE MITIGATION STRATEGIES FOR CONTROLLING EACH RISK. THESE RESEARCH PLANS HAVE SINCE BEEN THE BASIS FOR SOLICITED AND DIRECTED RESEARCH PROJECTS THAT ADD TO THE KNOWLEDGE BASE OF EACH RISK AND MAKE PROGRESS TOWARD FEASIBLE COUNTERMEASURES. THIS STRATEGY HAS PROVEN TO BE QUITE EFFECTIVE; COUNTERMEASURES HAVE BEEN DEVELOPED TO ADEQUATELY PREVENT, CONTROL OR TREAT MANY RISKS IN MULTIPLE MISSION SCENARIOS.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AO69A  
Thursday, June 8, 2017
$18,000.00
3600: Department of Veterans Affairs
36C24E: SAO EAST (00240E)

B: PURCHASE ORDER
MRI SCANS IGF::OT::IGF
Q301: MEDICAL- LABORATORY TESTING

  VA24017P0231     VA240-17-Q-0144  
Thursday, May 25, 2017
($1,063,365.00)
7500: Department of Health and Human Services
75Q801: AHRQ/HEALTHCARE RESEARCH QUALITY

D: DEFINITIVE CONTRACT
IGF::OT::IGF; JOHN M. EISENBERG CENTER FOR CLINICAL DECISIONS AND COMMUNICATIONS SCIENCE
R799: SUPPORT- MANAGEMENT: OTHER

  HHSA290201500002C  
Tuesday, May 23, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE TREATMENT AND EVALUATION UNITS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200010     HHSN272201300015I     FY.2017.A1B1C1D1.0048  
Tuesday, May 16, 2017
$0.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

F: COOPERATIVE AGREEMENT
THIS PROPOSAL FOR A TRANSLATIONAL RESEARCH INSTITUTE IS SUBMITTED ON BEHALF OF A CONSORTIUM OF NON-PROFIT ACADEMIC INSTITUTIONS IN RESPONSE TO NASA COOPERATIVE AGREEMENT NOTICE NNJ15548000C (CAN), RELEASED OCTOBER 30, 2015. THE CONSORTIUM IS LED BY BAYLOR COLLEGE OF MEDICINE (BCM), AND INCLUDES THE CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH) AND THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT). HRP WAS DESIGNED TO MANAGE AND FUND THE RESEARCH REQUIRED TO UNDERSTAND AND MITIGATE RISKS TO HUMAN HEALTH DURING SPACE FLIGHT MISSIONS. SINCE 2005, HRP HAS WORKED CLOSELY WITH NASA S CHIEF MEDICAL OFFICER, THE HEALTH AND MEDICAL TECHNICAL AUTHORITY, AND THE JOHNSON SPACE CENTER (JSC) HUMAN HEALTH AND PERFORMANCE DIRECTORATE TO DEFINE AND PRIORITIZE RISKS TO HUMANS DURING VARIOUS TYPES OF SPACE EXPLORATION MISSION. ONCE THE HIGHEST RISKS WERE IDENTIFIED, THE HRP DETERMINED RESEARCH PLANS (DOCUMENTED IN THE HRR) TO ADDRESS GAPS IN KNOWLEDGE AND DESCRIBE MITIGATION STRATEGIES FOR CONTROLLING EACH RISK. THESE RESEARCH PLANS HAVE SINCE BEEN THE BASIS FOR SOLICITED AND DIRECTED RESEARCH PROJECTS THAT ADD TO THE KNOWLEDGE BASE OF EACH RISK AND MAKE PROGRESS TOWARD FEASIBLE COUNTERMEASURES. THIS STRATEGY HAS PROVEN TO BE QUITE EFFECTIVE; COUNTERMEASURES HAVE BEEN DEVELOPED TO ADEQUATELY PREVENT, CONTROL OR TREAT MANY RISKS IN MULTIPLE MISSION SCENARIOS.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AO69A  
Friday, May 12, 2017
($15,000.00)
9700: Department of Defense
N00259: NAVAL MEDICAL CENTER SAN DIEGO CA

B: PURCHASE ORDER
IGF::OT::IGF CONSULTATION SEVICE - BASE YEAR
Q301: MEDICAL- LABORATORY TESTING

  N0025913P0098  
Thursday, May 11, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200009     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Friday, May 5, 2017
$0.00
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

B: PURCHASE ORDER
IGF::OT::IGF URINE ALBUMIN ANALYSES
R499: SUPPORT- PROFESSIONAL: OTHER

  HHSN275201600691P  
Friday, May 5, 2017
($171,193.71)
7500: Department of Health and Human Services
75N920: NATIONAL INSTITUTES OF HEALTH NHLBI

D: DEFINITIVE CONTRACT
ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN268201100006C  
Wednesday, May 3, 2017
$129,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

F: COOPERATIVE AGREEMENT
THIS PROPOSAL FOR A TRANSLATIONAL RESEARCH INSTITUTE IS SUBMITTED ON BEHALF OF A CONSORTIUM OF NON-PROFIT ACADEMIC INSTITUTIONS IN RESPONSE TO NASA COOPERATIVE AGREEMENT NOTICE NNJ15548000C (CAN), RELEASED OCTOBER 30, 2015. THE CONSORTIUM IS LED BY BAYLOR COLLEGE OF MEDICINE (BCM), AND INCLUDES THE CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH) AND THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT). HRP WAS DESIGNED TO MANAGE AND FUND THE RESEARCH REQUIRED TO UNDERSTAND AND MITIGATE RISKS TO HUMAN HEALTH DURING SPACE FLIGHT MISSIONS. SINCE 2005, HRP HAS WORKED CLOSELY WITH NASA S CHIEF MEDICAL OFFICER, THE HEALTH AND MEDICAL TECHNICAL AUTHORITY, AND THE JOHNSON SPACE CENTER (JSC) HUMAN HEALTH AND PERFORMANCE DIRECTORATE TO DEFINE AND PRIORITIZE RISKS TO HUMANS DURING VARIOUS TYPES OF SPACE EXPLORATION MISSION. ONCE THE HIGHEST RISKS WERE IDENTIFIED, THE HRP DETERMINED RESEARCH PLANS (DOCUMENTED IN THE HRR) TO ADDRESS GAPS IN KNOWLEDGE AND DESCRIBE MITIGATION STRATEGIES FOR CONTROLLING EACH RISK. THESE RESEARCH PLANS HAVE SINCE BEEN THE BASIS FOR SOLICITED AND DIRECTED RESEARCH PROJECTS THAT ADD TO THE KNOWLEDGE BASE OF EACH RISK AND MAKE PROGRESS TOWARD FEASIBLE COUNTERMEASURES. THIS STRATEGY HAS PROVEN TO BE QUITE EFFECTIVE; COUNTERMEASURES HAVE BEEN DEVELOPED TO ADEQUATELY PREVENT, CONTROL OR TREAT MANY RISKS IN MULTIPLE MISSION SCENARIOS.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AO69A  
Wednesday, April 12, 2017
$6,750.00
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

B: PURCHASE ORDER
IGF::OT::IGF-BAYLOR COLLEGE OF MEDICINE INC 1088193 [17-006670]
Q301: MEDICAL- LABORATORY TESTING

  HHSN275201700339P  
Wednesday, March 22, 2017
$0.00
7500: Department of Health and Human Services
75N920: NATIONAL INSTITUTES OF HEALTH NHLBI

D: DEFINITIVE CONTRACT
IGF::OT::IGF - B599 SPECIAL STUDIES/ANALYSIS- OTHER
B599: SPECIAL STUDIES/ANALYSIS- OTHER

  HHSN268201500015C     NHLBICSBHV2015134JS  
Thursday, March 16, 2017
$252,113.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF AWARD - A108 COTTON RAT MODEL FOR THE EVALUATION OF RSV VACCINES AND THERAPEUTICS
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN27200002     HHSN272201000004I  
Monday, March 13, 2017
$15,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
THIS PROPOSAL OUTLINES THE PLAN FOR MONITORING THE PHYSIOLOGICAL AND ANATOMICAL EFFECTS OF TWO DIFFERENT REGIMENS OF INTERMITTENT CENTRIFUGATION INDUCED ARTIFICIAL GRAVITY WITH FOCUS ON THE BRAIN, EYE, AND VESTIBULAR SYSTEM RESPONSES. THE SPECIFIC AIMS WILL INCLUDE: 1. INTEGRATIVE EVALUATION OF THE CEREBRAL PHYSIOLOGICAL EFFECTS OF AG DURING THE 60 DAY BED REST PERIOD USING BETWEEN GROUP AND WITHIN GROUP COMPARISONS, AND 2. ASSESSMENT OF THE ACUTE DYNAMIC CHANGES IN THE HUMAN BODY SYSTEMS RELATED TO THE CENTRIFUGATION REGIMEN. THE METHODS AND TECHNIQUES USED TO ACHIEVE THESE OBJECTIVES INCLUDE: NON-INVASIVE ASSESSMENT OF ICP, CEREBRAL BLOOD FLOW, CEREBRAL BLOOD VOLUME, CSF FLOW AND VOLUMES, OCULAR ANATOMY AND PHYSIOLOGY, AND NEUROVESTIBULAR FUNCTION. THIS PROPOSAL WILL DELIVER AN INTEGRATED VIEW OF THE PHYSIOLOGICAL, ANATOMICAL AND FUNCTIONAL EFFECTS OF INTERMITTENT CENTRIFUGATION (ARTIFICIAL GRAVITY) ON THE CEREBROVASCULAR, OCULAR AND VESTIBULAR SYSTEMS. THIS WILL PROVIDE IMPORTANT INSIGHTS INTO THE EFFECTIVENESS OF THIS FORM OF ARTIFICIAL GRAVITY TO COUNTERACT THE HEADWARD FLUID SHIFTING OF HEAD DOWN TILT; WHICH MAY YIELD IMPORTANT KNOWLEDGE ABOUT THE FUTURE UTILITY OF THIS METHOD AS A COUNTERMEASURE FOR THE SPACE-FLIGHT INDUCED HEADWARD FLUID SHIFTS AND THE VIIP SYNDROME.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX17AE04G  
Friday, March 10, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; VACCINE TREATMENT EVALUATION UNITS (EXTENSION)
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200006     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Thursday, February 23, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

B: IDC
IGF::OT::IGF; VACCINE AND TREATMENT EVALUATION UNITS (VTEU) PERIOD: SEPTEMBER 16, 2013 THROUGH SEPTEMBER 15, 2023
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Thursday, February 16, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
IMPLANT
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P2622  
Thursday, February 16, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
IMPLANT
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P2619  
Thursday, February 16, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
IMPLANT
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P2611  
Thursday, February 16, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
IMPLANT
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P2618  
Thursday, February 16, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
IMPLANT
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P2621  
Thursday, February 16, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
IMPLANT
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P2624  
Thursday, February 16, 2017
$3,700.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
IMPLANT
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P2614  
Tuesday, February 7, 2017
$203,024.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200009     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Tuesday, February 7, 2017
$196,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

F: COOPERATIVE AGREEMENT
THIS PROPOSAL FOR A TRANSLATIONAL RESEARCH INSTITUTE IS SUBMITTED ON BEHALF OF A CONSORTIUM OF NON-PROFIT ACADEMIC INSTITUTIONS IN RESPONSE TO NASA COOPERATIVE AGREEMENT NOTICE NNJ15548000C (CAN), RELEASED OCTOBER 30, 2015. THE CONSORTIUM IS LED BY BAYLOR COLLEGE OF MEDICINE (BCM), AND INCLUDES THE CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH) AND THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT). HRP WAS DESIGNED TO MANAGE AND FUND THE RESEARCH REQUIRED TO UNDERSTAND AND MITIGATE RISKS TO HUMAN HEALTH DURING SPACE FLIGHT MISSIONS. SINCE 2005, HRP HAS WORKED CLOSELY WITH NASA S CHIEF MEDICAL OFFICER, THE HEALTH AND MEDICAL TECHNICAL AUTHORITY, AND THE JOHNSON SPACE CENTER (JSC) HUMAN HEALTH AND PERFORMANCE DIRECTORATE TO DEFINE AND PRIORITIZE RISKS TO HUMANS DURING VARIOUS TYPES OF SPACE EXPLORATION MISSION. ONCE THE HIGHEST RISKS WERE IDENTIFIED, THE HRP DETERMINED RESEARCH PLANS (DOCUMENTED IN THE HRR) TO ADDRESS GAPS IN KNOWLEDGE AND DESCRIBE MITIGATION STRATEGIES FOR CONTROLLING EACH RISK. THESE RESEARCH PLANS HAVE SINCE BEEN THE BASIS FOR SOLICITED AND DIRECTED RESEARCH PROJECTS THAT ADD TO THE KNOWLEDGE BASE OF EACH RISK AND MAKE PROGRESS TOWARD FEASIBLE COUNTERMEASURES. THIS STRATEGY HAS PROVEN TO BE QUITE EFFECTIVE; COUNTERMEASURES HAVE BEEN DEVELOPED TO ADEQUATELY PREVENT, CONTROL OR TREAT MANY RISKS IN MULTIPLE MISSION SCENARIOS.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AO69A  
Wednesday, February 1, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF; VACCINE TREATMENT EVALUATION UNITS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200005     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Tuesday, January 31, 2017
$0.00
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

D: DEFINITIVE CONTRACT
IGF::OT::IGF - FETAL BODY COMPOSITION AND VOLUMES STUDY
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN275201500002C     RFPNIHNICHD20150001  
Tuesday, January 31, 2017
$53,897.00
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

D: DEFINITIVE CONTRACT
IGF::OT::IGF CARDIOVASCULAR PERFUSION SERVICES EXTEND SERVICES
Q502: MEDICAL- CARDIO-VASCULAR

  VA25616C0089  
Wednesday, January 18, 2017
$1,600,000.00
8000: National Aeronautics and Space Administration
80JSC0: NASA JOHNSON SPACE CENTER

F: COOPERATIVE AGREEMENT
NATIONAL SPACE BIOMEDICAL RESEARCH INSTITUTE
B537: SPECIAL STUDIES/ANALYSIS- MEDICAL/HEALTH

  NCC958  
Wednesday, January 18, 2017
$5,195,384.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF 1300015I BAYLOR UNIVERSITY; VTEU; TO 16-0057.C1D1.0058--15; ZIKA CAN 8026799; $5,195,384
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200013     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Friday, January 13, 2017
$3,024.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
CREWMEMBERS ON SPACEFLIGHT MISSIONS USE MEDICATIONS TO TREAT SPACEFLIGHT-ASSOCIATED CONDITIONS LIKE SPACE ADAPTATION SYNDROME AS WELL AS COMMON ORDINARY COMPLAINTS. THEY DO SO UNDER THE REMOTE GUIDANCE OF THEIR FLIGHT SURGEONS, WHO BASE PRESCRIPTIONS ON THEIR KNOWLEDGE AND EXPERIENCE IN TERRESTRIAL MEDICINE. HOWEVER, EVEN AFTER DECADES OF SPACEFLIGHT MISSIONS, WE DO NOT KNOW IF MEDICATIONS ACT THE SAME IN THE SPACEFLIGHT ENVIRONMENT AS THEY DO ON EARTH. ASPECTS OF THE SPACEFLIGHT ENVIRONMENT (LOW GRAVITY, RADIATION EXPOSURE, CLOSED ENVIRONMENT, STRESS) HAVE BEEN SHOWN TO ALTER HUMAN PHYSIOLOGY. FROM FIRST PRINCIPLES, SOME OF THESE PHYSIOLOGICAL CHANGES COULD BE EXPECTED TO ALTER EITHER PHARMACOKINETICS (PK, HOW THE BODY ABSORBS, DISTRIBUTES, METABOLIZE AND EXCRETES ADMINISTERED MEDICATIONS) OR PHARMACODYNAMICS (PD, RECEPTORS OR SIGNALLING SYSTEMS THAT ARE THE TARGETS OF MEDICATION ACTION). ANECDOTAL DATA HAS SUGGESTED THAT, AT LEAST FOR CERTAIN MEDICATIONS OR INDICATIONS, INFLIGHT MEDICATION EFFICACY IS POOR, AND SPACEFLIGHT CREW USE HIGH DOSES, REPEATED DOSES, OR EVEN EXPERIENCE APPARENT TREATMENT FAILURES; FORTUNATELY NONE OF THESE EPISODES HAS BEEN SERIOUS ENOUGH TO CAUSE INJURY OR EVACUATION FROM LOW-EARTH ORBIT (LEO). HOWEVER, IN ORDER TO PREPARE FOR EXPLORATION MISSIONS WHERE SPEEDY EVACUATION TO EARTH MAY NOT BE A POSSIBILITY, THE LIKELIHOOD OF UNEXPECTED MEDICATION ACTION MUST BE DETERMINED. NEW STUDIES HAVE YIELDED THE FIRST DOCUMENTED EVIDENCE OF APPARENT TREATMENT FAILURES IN LOW EARTH ORBIT. THESE INSTANCES COULD BE EXPLAINED BY ALTERATIONS IN PK OR PD. THE CENTRAL HYPOTHESIS OF THIS PROPOSAL IS THAT THE SPACEFLIGHT ENVIRONMENT ALTERS HUMAN PHYSIOLOGY IN WAYS THAT AFFECT HOW MEDICATIONS ULTIMATELY EXERT THEIR ACTIONS, EITHER BY CHANGING PK OR PD. SPECIFICALLY, WE PROPOSE TO: (1) TEST THE HYPOTHESIS THAT PK FOLLOWING ADMINISTRATION OF A MEDICATION IS DIFFERENT DURING SPACEFLIGHT AS COMPARED TO GROUNDBASED DATA FROM THE SAME SUBJECT, AND (2) TEST THE HYPOTHESIS THAT MEDICATION ACTION (PD) IS DIFFERENT DURING SPACEFLIGHT AS COMPARED TO GROUND-BASED DATA FROM THE SAME SUBJECT. WE PROPOSE TO TEST OUR HYPOTHESIS WITH THREE UNRELATED MEDICATIONS COMMONLY USED ON SPACEFLIGHT MISSIONS: A NONBENZODIAZEPINE HYPNOTIC, A STIMULANT, AND AN ANTIHISTAMINE WITH ANTINAUSEA ACTION. THESE MEDICATIONS ALL HAVE TARGETS IN THE CENTRAL NERVOUS SYSTEM, AND SHARE ACTION ON SLEEP OR WAKEFULNESS, PERMITTING USE OF THE SAME SUITE OF PD MEASURES. WE PROPOSE TO MEASURE PK FOR 3 MEDICATIONS FREQUENTLY USED BY CREWMEMBERS IN TWO DIFFERENT ENVIRONMENTS: ON EARTH AND DURING A SPACEFLIGHT MISSION. CIRCULATING CONCENTRATIONS IN THE BLOODSTREAM WILL BE MEASURED OVER TIME AFTER MEDICATION ADMINISTRATION, PERMITTING MODELED ESTIMATION OF ABSORPTION RATES AND METABOLISM/EXCRETION RATES. SAME-SUBJECT COMPARISONS USING PRE-FLIGHT AND POST-FLIGHT TEST SESSIONS WILL PERMIT MEASUREMENT OF SAME-SUBJECT VARIABILITY THAT WILL PROVIDE A BASELINE FOR DETERMINATION OF CLINICALLY RELEVANT CHANGES DURING SPACEFLIGHT. SPACEFLIGHT VS. GROUND DIFFERENCES IN MEDICATION-ASSOCIATED EFFECTS ON SLEEP, WAKEFULNESS, AND SEVERAL MEASURES OF COGNITIVE FUNCTION WILL BE USED AS MEASURES OF PHARMCODYNAMICS.THIS STUDY WILL DETERMINE IF THE LEO ENVIRONMENT OF THE ISS ALTERS THE ACTIONS OF THREE COMMON MEDICATIONS. A LIKELY OUTCOME, RELEVANT FOR NASA MISSIONS, IS OPTIMIZED DOSING RECOMMENDATIONS FOR ONE OR MORE OF THESE MEDICATIONS. IN MORE GENERAL TERMS, THE RESULTS OF THIS STUDY WILL INDICATE THE LIKELIHOOD AND MAGNITUDE OF ANY SPACEFLIGHT-ASSOCIATED PK OR PD CHANGES, AND THUS HELP TO DETERMINE FUTURE RESEARCH PRIORITIES. THE GENERAL POPULATION, WHO ALSO USE THESE MEDICATIONS, ARE ALSO LIKELY TO BENEFIT FROM ADDITIONAL UNDERSTANDING OF HOW THESE MEDICATIONS INTERACT WITH THE HUMAN BODY.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AG97G  
Thursday, January 12, 2017
$0.00
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

D: DEFINITIVE CONTRACT
FINAL_CLOSE_PROCESS -
AJ62: R&D- GENERAL SCIENCE/TECHNOLOGY: PSYCHOLOGICAL SCIENCES (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN275200403362C  
Wednesday, January 11, 2017
$60,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
DOSE TRACKER APPLICATION FOR MONITORING CREW MEDICATION USAGE, SYMPTOMS, AND ADVERSE EFFECTS DURING MISSIONS DO MEDICATIONS USED DURING SPACEFLIGHTS WORK THE SAME AS THEY DO ON EARTH? THIS SINGLE QUESTION UNDERLIES MOST OF THE UNKNOWNS WITHIN NASA S HUMAN RESEARCH PROGRAM RISK OF CLINICALLY RELEVANT UNPREDICTED EFFECTS OF MEDICATION. DURING SPACEFLIGHT, THE BODY UNDERGOES A NUMBER OF PHYSIOLOGICAL CHANGES THAT ARE EXPECTED TO RESULT IN ALTERED INTERACTIONS WITH ADMINISTERED MEDICATIONS, BUT IT IS NOT YET KNOWN IF, OR TO WHAT EXTENT, THESE ACTUALLY OCCUR. THE POTENTIAL FOR THERAPEUTICALLY RELEVANT ALTERATION IN EITHER PHARMACOKINETICS (HOW THE BODY HANDLES ADMINISTERED MEDICATIONS) OR PHARMACODYNAMICS (HOW ADMINISTERED MEDICATIONS ACT UPON THE BODY) HAS LONG BEEN A CONCERN. THIS OBSERVATIONAL EPIDEMIOLOGICAL STUDY IS A PROACTIVE STEP TOWARD ADDRESSING THIS ISSUE VIA REGULAR DIRECT QUESTIONING OF CREWMEMBER VOLUNTEERS, A MODEL THAT THE JSC NUTRITIONAL BIOCHEMISTRY DISCIPLINE HAS PROVEN TO BE BOTH FEASIBLE AND USEFUL. A TABLET- OR HANDHELD DEVICE-BASED QUESTIONNAIRE WILL BE USED TO PERMIT FAST AND EFFICIENT COLLECTION OF DATA REGARDING CREWMEMBERS MEDICATION USE ON A NEAR REAL-TIME BASIS, ELIMINATING THE CURRENT PROBLEMS ASSOCIATED WITH RECALL OVER PERIODS OF WEEKS. SPECIFIC QUESTIONS REGARDING MEDICATION USE (SOMEWHAT DIFFERENT FROM THE QUESTIONS THAT PHYSICIANS ASK REGARDING PATIENT HEALTH) WILL BE ASKED OF EACH PARTICIPATING CREWMEMBER. THE DATA COLLECTION PROCESS WILL BE STREAMLINED BY USING A FLEXIBLY PROGRAMMED COMPUTERIZED SURVEY APPLICATION THAT LEVERAGES THE LIMITED MEDICATION CHOICES ABOARD, THE DOSES AVAILABLE, TYPICAL DOSING FREQUENCY, AND SIDE EFFECTS ASSOCIATED WITH EACH MEDICATION TO PROVIDE AN INDIVIDUALIZED SHORT QUESTIONNAIRE FOR EACH MEDICATION USE BY THE CREWMEMBER. CODED (DE-IDENTIFIED) DATA WILL BE DELIVERED WEEKLY TO A SECURE SERVER ON THE GROUND FOR ANALYSIS BY STUDY INVESTIGATORS. POST-FLIGHT (AFTER RE-ADAPTATION TO EARTH S GRAVITY), EACH PARTICIPATING CREWMEMBER WILL REPEAT RECORDING THEIR MEDICATION USAGE, SO THAT THEIR GROUND MEDICATION USAGE FREQUENCIES, DOSES, AND PERCEPTIONS MAY BE COMPARED TO THOSE RECORDED DURING FLIGHT.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AK78G  
Tuesday, January 10, 2017
$706,378.00
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

D: DEFINITIVE CONTRACT
IGF::OT::IGF - FETAL BODY COMPOSITION AND VOLUMES STUDY
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN275201500002C     RFPNIHNICHD20150001  
Monday, January 9, 2017
$2,972.16
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

B: PURCHASE ORDER
IGF::OT::IGF - BAYLOR COLLEGE OF MEDICINE INC:1088193 [16-013762]
Q301: MEDICAL- LABORATORY TESTING

  HHSN275201600697P  
Wednesday, January 4, 2017
$0.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200009     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Tuesday, January 3, 2017
$880,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

F: COOPERATIVE AGREEMENT
THIS PROPOSAL FOR A TRANSLATIONAL RESEARCH INSTITUTE IS SUBMITTED ON BEHALF OF A CONSORTIUM OF NON-PROFIT ACADEMIC INSTITUTIONS IN RESPONSE TO NASA COOPERATIVE AGREEMENT NOTICE NNJ15548000C (CAN), RELEASED OCTOBER 30, 2015. THE CONSORTIUM IS LED BY BAYLOR COLLEGE OF MEDICINE (BCM), AND INCLUDES THE CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH) AND THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (MIT). HRP WAS DESIGNED TO MANAGE AND FUND THE RESEARCH REQUIRED TO UNDERSTAND AND MITIGATE RISKS TO HUMAN HEALTH DURING SPACE FLIGHT MISSIONS. SINCE 2005, HRP HAS WORKED CLOSELY WITH NASA S CHIEF MEDICAL OFFICER, THE HEALTH AND MEDICAL TECHNICAL AUTHORITY, AND THE JOHNSON SPACE CENTER (JSC) HUMAN HEALTH AND PERFORMANCE DIRECTORATE TO DEFINE AND PRIORITIZE RISKS TO HUMANS DURING VARIOUS TYPES OF SPACE EXPLORATION MISSION. ONCE THE HIGHEST RISKS WERE IDENTIFIED, THE HRP DETERMINED RESEARCH PLANS (DOCUMENTED IN THE HRR) TO ADDRESS GAPS IN KNOWLEDGE AND DESCRIBE MITIGATION STRATEGIES FOR CONTROLLING EACH RISK. THESE RESEARCH PLANS HAVE SINCE BEEN THE BASIS FOR SOLICITED AND DIRECTED RESEARCH PROJECTS THAT ADD TO THE KNOWLEDGE BASE OF EACH RISK AND MAKE PROGRESS TOWARD FEASIBLE COUNTERMEASURES. THIS STRATEGY HAS PROVEN TO BE QUITE EFFECTIVE; COUNTERMEASURES HAVE BEEN DEVELOPED TO ADEQUATELY PREVENT, CONTROL OR TREAT MANY RISKS IN MULTIPLE MISSION SCENARIOS.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AO69A  
Sunday, January 1, 2017
$245,738.98
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

C: DELIVERY ORDER
IGF::CT::IGF LIVER KIDNEY TRANSPLANT SERVICES TASK ORDER ISSUED FROM IDIQ CONTRACT. PERIOD OF PERFORMANCE 01-01-2017 THROUGH 06-30-2017.
Q523: MEDICAL- SURGERY

  VA25617J0295     VA25616D0126  
Sunday, January 1, 2017
$0.00
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

B: IDC
IGF::CT::IGF LIVER KIDNEY TRANSPLANT SERVICES, PERIOD OF PERFORMANCE 01-01-2017 THROUGH 06-30-2017.
Q523: MEDICAL- SURGERY

  VA25616D0126     VA256-16-R-0832  
Tuesday, December 27, 2016
$53,897.00
3600: Department of Veterans Affairs
36C256: 256-NETWORK CONTRACT OFC 16(00256)

D: DEFINITIVE CONTRACT
IGF::OT::IGF CARDIOVASCULAR PERFUSION SERVICES EXTEND SERVICES
Q502: MEDICAL- CARDIO-VASCULAR

  VA25616C0089  
Tuesday, December 20, 2016
$18,833.00
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

D: DEFINITIVE CONTRACT
IGF::OT::IGF - FETAL BODY COMPOSITION AND VOLUMES STUDY
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN275201500002C     RFPNIHNICHD20150001  
Thursday, December 15, 2016
$2,500,000.00
8000: National Aeronautics and Space Administration
80JSC0: NASA JOHNSON SPACE CENTER

F: COOPERATIVE AGREEMENT
NATIONAL SPACE BIOMEDICAL RESEARCH INSTITUTE
B537: SPECIAL STUDIES/ANALYSIS- MEDICAL/HEALTH

  NCC958  
Wednesday, December 14, 2016
($184,782.25)
7500: Department of Health and Human Services
75N94A: NATIONAL INSTITUTES OF HEALTH NIDDK

C: DELIVERY ORDER
FINAL_CLOSE_PROCESS -OTHER FUNCTIONS: THE PURPOSE OF THIS MODIFICATION IS DEOBLIGATE FUNDS FOR CLOSE OUT.
AN11: R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)

  HHSN27200001     HHSN272201000004I  
Monday, December 12, 2016
($115,593.93)
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF 1300015I BAYLOR UNIVERSITY; VTEU; TASK A1; BIOD CAN 8470038; $333,338
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200002     HHSN272201300015I     NIAIDDMIDNIHAI2012144  
Tuesday, December 6, 2016
$3,945.00
3600: Department of Veterans Affairs
36P256: 256P-NETWORK CONTRACT OFFICE 16

B: PURCHASE ORDER
CORNEA
6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

  VA25617P1105  
Wednesday, November 30, 2016
$40,000.00
8000: National Aeronautics and Space Administration
80NSSC: NASA SHARED SERVICES CENTER

G: GRANT FOR RESEARCH
CREWMEMBERS ON SPACEFLIGHT MISSIONS USE MEDICATIONS TO TREAT SPACEFLIGHT-ASSOCIATED CONDITIONS LIKE SPACE ADAPTATION SYNDROME AS WELL AS COMMON ORDINARY COMPLAINTS. THEY DO SO UNDER THE REMOTE GUIDANCE OF THEIR FLIGHT SURGEONS, WHO BASE PRESCRIPTIONS ON THEIR KNOWLEDGE AND EXPERIENCE IN TERRESTRIAL MEDICINE. HOWEVER, EVEN AFTER DECADES OF SPACEFLIGHT MISSIONS, WE DO NOT KNOW IF MEDICATIONS ACT THE SAME IN THE SPACEFLIGHT ENVIRONMENT AS THEY DO ON EARTH. ASPECTS OF THE SPACEFLIGHT ENVIRONMENT (LOW GRAVITY, RADIATION EXPOSURE, CLOSED ENVIRONMENT, STRESS) HAVE BEEN SHOWN TO ALTER HUMAN PHYSIOLOGY. FROM FIRST PRINCIPLES, SOME OF THESE PHYSIOLOGICAL CHANGES COULD BE EXPECTED TO ALTER EITHER PHARMACOKINETICS (PK, HOW THE BODY ABSORBS, DISTRIBUTES, METABOLIZE AND EXCRETES ADMINISTERED MEDICATIONS) OR PHARMACODYNAMICS (PD, RECEPTORS OR SIGNALLING SYSTEMS THAT ARE THE TARGETS OF MEDICATION ACTION). ANECDOTAL DATA HAS SUGGESTED THAT, AT LEAST FOR CERTAIN MEDICATIONS OR INDICATIONS, INFLIGHT MEDICATION EFFICACY IS POOR, AND SPACEFLIGHT CREW USE HIGH DOSES, REPEATED DOSES, OR EVEN EXPERIENCE APPARENT TREATMENT FAILURES; FORTUNATELY NONE OF THESE EPISODES HAS BEEN SERIOUS ENOUGH TO CAUSE INJURY OR EVACUATION FROM LOW-EARTH ORBIT (LEO). HOWEVER, IN ORDER TO PREPARE FOR EXPLORATION MISSIONS WHERE SPEEDY EVACUATION TO EARTH MAY NOT BE A POSSIBILITY, THE LIKELIHOOD OF UNEXPECTED MEDICATION ACTION MUST BE DETERMINED. NEW STUDIES HAVE YIELDED THE FIRST DOCUMENTED EVIDENCE OF APPARENT TREATMENT FAILURES IN LOW EARTH ORBIT. THESE INSTANCES COULD BE EXPLAINED BY ALTERATIONS IN PK OR PD. THE CENTRAL HYPOTHESIS OF THIS PROPOSAL IS THAT THE SPACEFLIGHT ENVIRONMENT ALTERS HUMAN PHYSIOLOGY IN WAYS THAT AFFECT HOW MEDICATIONS ULTIMATELY EXERT THEIR ACTIONS, EITHER BY CHANGING PK OR PD. SPECIFICALLY, WE PROPOSE TO: (1) TEST THE HYPOTHESIS THAT PK FOLLOWING ADMINISTRATION OF A MEDICATION IS DIFFERENT DURING SPACEFLIGHT AS COMPARED TO GROUNDBASED DATA FROM THE SAME SUBJECT, AND (2) TEST THE HYPOTHESIS THAT MEDICATION ACTION (PD) IS DIFFERENT DURING SPACEFLIGHT AS COMPARED TO GROUND-BASED DATA FROM THE SAME SUBJECT. WE PROPOSE TO TEST OUR HYPOTHESIS WITH THREE UNRELATED MEDICATIONS COMMONLY USED ON SPACEFLIGHT MISSIONS: A NONBENZODIAZEPINE HYPNOTIC, A STIMULANT, AND AN ANTIHISTAMINE WITH ANTINAUSEA ACTION. THESE MEDICATIONS ALL HAVE TARGETS IN THE CENTRAL NERVOUS SYSTEM, AND SHARE ACTION ON SLEEP OR WAKEFULNESS, PERMITTING USE OF THE SAME SUITE OF PD MEASURES. WE PROPOSE TO MEASURE PK FOR 3 MEDICATIONS FREQUENTLY USED BY CREWMEMBERS IN TWO DIFFERENT ENVIRONMENTS: ON EARTH AND DURING A SPACEFLIGHT MISSION. CIRCULATING CONCENTRATIONS IN THE BLOODSTREAM WILL BE MEASURED OVER TIME AFTER MEDICATION ADMINISTRATION, PERMITTING MODELED ESTIMATION OF ABSORPTION RATES AND METABOLISM/EXCRETION RATES. SAME-SUBJECT COMPARISONS USING PRE-FLIGHT AND POST-FLIGHT TEST SESSIONS WILL PERMIT MEASUREMENT OF SAME-SUBJECT VARIABILITY THAT WILL PROVIDE A BASELINE FOR DETERMINATION OF CLINICALLY RELEVANT CHANGES DURING SPACEFLIGHT. SPACEFLIGHT VS. GROUND DIFFERENCES IN MEDICATION-ASSOCIATED EFFECTS ON SLEEP, WAKEFULNESS, AND SEVERAL MEASURES OF COGNITIVE FUNCTION WILL BE USED AS MEASURES OF PHARMCODYNAMICS.THIS STUDY WILL DETERMINE IF THE LEO ENVIRONMENT OF THE ISS ALTERS THE ACTIONS OF THREE COMMON MEDICATIONS. A LIKELY OUTCOME, RELEVANT FOR NASA MISSIONS, IS OPTIMIZED DOSING RECOMMENDATIONS FOR ONE OR MORE OF THESE MEDICATIONS. IN MORE GENERAL TERMS, THE RESULTS OF THIS STUDY WILL INDICATE THE LIKELIHOOD AND MAGNITUDE OF ANY SPACEFLIGHT-ASSOCIATED PK OR PD CHANGES, AND THUS HELP TO DETERMINE FUTURE RESEARCH PRIORITIES. THE GENERAL POPULATION, WHO ALSO USE THESE MEDICATIONS, ARE ALSO LIKELY TO BENEFIT FROM ADDITIONAL UNDERSTANDING OF HOW THESE MEDICATIONS INTERACT WITH THE HUMAN BODY.
AR21: R&D- SPACE: SCIENCE/APPLICATIONS (BASIC RESEARCH)

  NNX16AG97G  
Monday, November 28, 2016
$0.00
7500: Department of Health and Human Services
75N940: NATIONAL INSTITUTES OF HEALTH NICHD

D: DEFINITIVE CONTRACT
FINAL_CLOSE_PROCESS -
AJ62: R&D- GENERAL SCIENCE/TECHNOLOGY: PSYCHOLOGICAL SCIENCES (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN275200403362C  
Tuesday, November 22, 2016
$795,000.00
8000: National Aeronautics and Space Administration
80JSC0: NASA JOHNSON SPACE CENTER

F: COOPERATIVE AGREEMENT
NATIONAL SPACE BIOMEDICAL RESEARCH INSTITUTE
B537: SPECIAL STUDIES/ANALYSIS- MEDICAL/HEALTH

  NCC958  
Monday, November 21, 2016
$3,143,394.00
7500: Department of Health and Human Services
75Q801: AHRQ/HEALTHCARE RESEARCH QUALITY

D: DEFINITIVE CONTRACT
IGF::OT::IGF; JOHN M. EISENBERG CENTER FOR CLINICAL DECISIONS AND COMMUNICATIONS SCIENCE
R799: SUPPORT- MANAGEMENT: OTHER

  HHSA290201500002C  
Thursday, November 17, 2016
$2,500.00
3600: Department of Veterans Affairs
36C506: 506-ANN ARBOR (00506)

D: DEFINITIVE CONTRACT
IGF::OT::IGF PRINCIPAL RESEARCH INVESTIGATOR ON HSR&D PROJECT.
R497: SUPPORT- PROFESSIONAL: PERSONAL SERVICES CONTRACTS

  VA25115C0187     VA251-15-Q-0422  
Thursday, October 27, 2016
$303,349.00
7500: Department of Health and Human Services
75N930: NATIONAL INSTITUTES OF HEALTH NIAID

C: DELIVERY ORDER
IGF::OT::IGF VACCINE AND TREATMENT EVALUATION UNITS (VTEU) PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS TASK AREA B-D POPULATION PHARMACOKINETIC ANALYSES TASK ORDER 16-0075.B2C2D2.0053
AN12: R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT)

  HHSN27200012     HHSN272201300015I     NIAIDDMIDNIHAI2012144